- Home
- ORC vs CDXC Comparison
ORC vs CDXC Comparison
Compare ORC & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- CDXC
- Stock Information
- Founded
- ORC 2010
- CDXC 1999
- Country
- ORC United States
- CDXC United States
- Employees
- ORC N/A
- CDXC N/A
- Industry
- ORC Real Estate Investment Trusts
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- ORC Real Estate
- CDXC Health Care
- Exchange
- ORC Nasdaq
- CDXC Nasdaq
- Market Cap
- ORC 611.8M
- CDXC 572.6M
- IPO Year
- ORC 2013
- CDXC N/A
- Fundamental
- Price
- ORC $8.04
- CDXC $5.93
- Analyst Decision
- ORC Buy
- CDXC Strong Buy
- Analyst Count
- ORC 2
- CDXC 2
- Target Price
- ORC $9.50
- CDXC $8.00
- AVG Volume (30 Days)
- ORC 1.6M
- CDXC 732.2K
- Earning Date
- ORC 01-30-2025
- CDXC 10-31-2024
- Dividend Yield
- ORC 18.02%
- CDXC N/A
- EPS Growth
- ORC N/A
- CDXC N/A
- EPS
- ORC 1.01
- CDXC 0.02
- Revenue
- ORC $75,695,000.00
- CDXC $91,668,000.00
- Revenue This Year
- ORC N/A
- CDXC $18.64
- Revenue Next Year
- ORC N/A
- CDXC $20.72
- P/E Ratio
- ORC $7.91
- CDXC $301.89
- Revenue Growth
- ORC N/A
- CDXC 9.95
- 52 Week Low
- ORC $7.41
- CDXC $1.36
- 52 Week High
- ORC $9.08
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- ORC 56.84
- CDXC 40.09
- Support Level
- ORC $8.01
- CDXC $5.87
- Resistance Level
- ORC $8.21
- CDXC $7.79
- Average True Range (ATR)
- ORC 0.12
- CDXC 0.34
- MACD
- ORC 0.01
- CDXC -0.24
- Stochastic Oscillator
- ORC 64.53
- CDXC 6.67
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.